#lykos — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #lykos, aggregated by home.social.
-
#JoeRogan interviews #RickDoblin, Ph.D., the founder and president of the Multidisciplinary Association for Psychedelic Studies (#MAPS), a nonprofit established in 1986 to advance evidence-based psychedelic therapy and end prohibition. MAPS incubated #Lykos Therapeutics (formerly MAPS Public Benefit Corporation) which is leading drug development of MDMA-assisted therapy for #PTSD.
-
From where I stand, the linked article below looks like an opportunistic partisan move. In my view, people from both sides of the dispute (#MAPS AND #Psymposia) managed to slow down the progress of #psychedelicMedicine (maybe for good).
But I agree with Ms. Devenot that, specially by tagging #Left on the title, it is a "transparently partisan attack" that "politicized whistleblowers to appeal to the #Trump administration on behalf of a #pharmaceuticalcompany." (#Lykos) -
From where I stand, the linked article below looks like an opportunistic partisan move. In my view, people from both sides of the dispute (#MAPS AND #Psymposia) managed to slow down the progress of #psychedelicMedicine (maybe for good).
But I agree with Ms. Devenot that, specially by tagging #Left on the title, it is a "transparently partisan attack" that "politicized whistleblowers to appeal to the #Trump administration on behalf of a #pharmaceuticalcompany." (#Lykos) -
From where I stand, the linked article below looks like an opportunistic partisan move. In my view, people from both sides of the dispute (#MAPS AND #Psymposia) managed to slow down the progress of #psychedelicMedicine (maybe for good).
But I agree with Ms. Devenot that, specially by tagging #Left on the title, it is a "transparently partisan attack" that "politicized whistleblowers to appeal to the #Trump administration on behalf of a #pharmaceuticalcompany." (#Lykos) -
From where I stand, the linked article below looks like an opportunistic partisan move. In my view, people from both sides of the dispute (#MAPS AND #Psymposia) managed to slow down the progress of #psychedelicMedicine (maybe for good).
But I agree with Ms. Devenot that, specially by tagging #Left on the title, it is a "transparently partisan attack" that "politicized whistleblowers to appeal to the #Trump administration on behalf of a #pharmaceuticalcompany." (#Lykos) -
From where I stand, the linked article below looks like an opportunistic partisan move. In my view, people from both sides of the dispute (#MAPS AND #Psymposia) managed to slow down the progress of #psychedelicMedicine (maybe for good).
But I agree with Ms. Devenot that, specially by tagging #Left on the title, it is a "transparently partisan attack" that "politicized whistleblowers to appeal to the #Trump administration on behalf of a #pharmaceuticalcompany." (#Lykos) -
More bad news for psychedelic drug company: FDA expands probe after rejection - Enlarge / President of Multidisciplinary Association for Psychedelic S... - https://arstechnica.com/?p=2045406 #psychedelics #science #health #lykos #maps #mdma #ptsd
-
A @STAT exclusive: Rick Doblin's first interview after
• Lykos' #MDMA treatment was rejected by the FDA
• 3 of its papers were retracted
• #Lykos laid off workers + ejected Doblin from its board
• MAPS laid off workersHe came out firing.
https://www.statnews.com/2024/08/17/mdma-psychedelics-rick-doblin-lykos-exit
-
"The #FDA and its advisors identified flaws in the design of the clinical trials, missing data, and a variety of biases in people involved with the trials, including an alleged cult-like support of #psychedelics. #Lykos is a commercial spinoff of the psychedelic advocacy nonprofit Multidisciplinary Association for Psychedelic Studies (#MAPS)."
https://arstechnica.com/science/2024/08/mdma-for-ptsd-three-studies-retracted-on-heels-of-fda-rejection/ -
"#Lykos itself was bracing for a negative verdict from the agency amidst a number of negative appraisals in recent months. Those included one of #FDA’s own advisory committees pointing to flaws in the study design & conduct.
However, insiders are surprised by just how harsh FDA’s CRL appears to have been, with the agency requesting an additional Phase 3—a very, very tall ask for the small company."
#MDMA #PTSD
https://psychedelicalpha.com/news/breaking-fda-rejects-lykos-therapeutics-mdma-assisted-therapy-for-ptsd -
Flawed, scandalous trials tank FDA expert support for MDMA therapy - Enlarge / MDMA pills up close. (credit: Getty | Universal History Archi... - https://arstechnica.com/?p=2029048 #clinicaltrial #psychotherapy #unblinded #blinding #science #health #lykos #bias #maps #mdma #ptsd #fda
